Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy of atorvastatin treatment during 3
months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.